Особенности течения рецидивов и рефрактерных форм Т-лимфобластной лимфомы у детей
https://doi.org/10.24287/1726-1708-2020-19-3-84-89
Аннотация
Об авторах
З. А. АбашидзеРоссия
врач-гематолог боксированного отделения гематологии/онкологии,
117997, Москва, ул. Саморы Машела, 1
Ю. Ю. Дьяконова
Россия
117997, Москва, ул. Саморы Машела, 1
Н. В. Мякова
Россия
117997, Москва, ул. Саморы Машела, 1
Список литературы
1. Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R., et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the Berlin‐Frankfurt‐Muenster group. J Clin Oncol 2009; 27 (20): 3363–9. DOI: 10.1200/JCO.2008.19.3367
2. Румянцев А.Г., Масчан А.А., Жуковская Е.В. Федеральные клинические рекомендации. Детская гематология. М.: ГЭОТАР-Медиа; 2015.
3. Burkhardt B., Mueller S., Khanam T., Perkins S.L. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol 2016; 173 (4): 545–59. DOI: 10.1111/bjh.14017
4. El-Mallawany N.K., Frazer J.K., Van Vlierberghe P., Ferrando A. A., Perkins S., Lim M., et al. Pediatric T-and NK-cell lymphomas: New biologic insights and treatment strategies. Blood Cancer J 2012; 2(4): е65. DOI: 10.1038/bcj.2012.8
5. T-lymphoblastic lymphoma. World Health Organization (WHO), 2017.
6. Kobayashi R., Takimoto T., Nakazawa A., Fujita N., Akazai A., Yamato K., et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T‐acute lymphoblastic leukemia: long‐term comparison of outcomes in the JACLS NHL T‐98 and ALL T‐97 protocols. Int J Hematol 2014; 99 (6): 743–9. DOI: 10.1007/s12185-014-1585-z
7. Kobrinsky N.L., Sposto R., Shah N.R., Anderson JR, De Laat C, Morse M., et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19(9): 2390–6.
8. Michaux K., Bergeron C., Gandemer V., Mechinaud F., Uyttebroeck A., Bertrand Y.; SFCE and the EORTC children leukemia group. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols. Pediatr Blood Cancer 2016; 63(7): 1214–21. DOI: 10.1002/pbc.25990
9. Callens C., Baleydier F., Lengline E., Ben Abdelali R., Petit A., Villarese P., et al. Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma. J Clin Oncol 2012; 30(16): 1966– 73. DOI: 10.1200/JCO.2011.39.7661
10. Bonn B.R., Rohde M., Zimmermann M., Krieger D., Oschlies I., Niggli F., et al. Incidence and prognostic relevance of genetic variations in T‐cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013; 121(16): 3153–60.
11. Balbach S.T., Makarova O., Bonn B.R., Zimmermann M., Rohde M., Oschlies I. et al. Proposal of a genetic classifier for risk group stratification in pediatric T‐cell lymphoblastic lymphoma reveals differences from adult T‐cell lymphoblastic leukemia. Leukemia 2016; 30 (4): 970-3. DOI: 10.1038/leu.2015.203.
12. Kobrinsky N.L., Sposto R., Shah N.R., Anderson J.R., DeLaat C., Morse M. et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19(9):2390–6.
13. Harris R.E., Termuhlen A.M., Smith L.M. Lynch J., Henry M.M., Perkins S.L., et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children,s Oncology Group Study A5962. Biol Blood Marrow Transplant 2011; 17(2): 249– 58. DOI: 10.1016/j.bbmt.2010.07.002
14. Gross T.G., Hale G.A., He W., Camitta B.M., Sanders J.E., Cairo M.S. et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16(2): 223–30. DOI: 10.1016/j.bbmt.2009.09.021.
15. Dunsmore K.P., Devidas M., Linda S.B., Borowitz M.J., Winick N., Hunger S.P., et al. Pilot study of nelarabine in combination with intensive chemotherapy in highrisk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30(22): 2753–9. DOI: 10.1200/JCO.2011.40.8724
16. Валиев Т.Т. Клиническая характеристика и результаты терапии рецидивов/ рефрактерных форм неходжкинских лимфом у детей: обзор литературы и анализ собственных данных. Онкогематология 2018; 13(2): 21–31. DOI: 10.17650/1818-8346-2018-13-2-21-31
17. Cooper T.M., Razzouk B.I., Gerbing R., Alonzo T.A., Adlard K., Raetz E., et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children’s Oncology Group. Pediatr Blood Cancer 2013; 60(7): 1141–7. DOI: 10.1002/pbc.24398
18. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anticancer therapy. Drug Discov Today 2010; 15 (5–6): 243–9. DOI: 10.1016/j.drudis. 2010.01.008
19. Schmidt E., Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol 2013; 30(6): 484– 508. DOI: 10.3109/08880018.2013.789574
Рецензия
Для цитирования:
Абашидзе З.А., Дьяконова Ю.Ю., Мякова Н.В. Особенности течения рецидивов и рефрактерных форм Т-лимфобластной лимфомы у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(3):84-89. https://doi.org/10.24287/1726-1708-2020-19-3-84-89
For citation:
Abashidze Z.A., Dyakonova U.U., Myakova N.V. Features of relapses and refractory forms of T-lymphoblastic lymphoma in children. Pediatric Hematology/Oncology and Immunopathology. 2020;19(3):84-89. (In Russ.) https://doi.org/10.24287/1726-1708-2020-19-3-84-89